OCT 06, 2015 08:04 AM PDT

Curing Hepatitis C and the Potential for Vaccines

WRITTEN BY: Kara Marker
The Nova Scotia Health Authority in Canada is leading a hepatitis C study at the Prince Edward Island's (PEI) provincial correctional center. Hepatitis C is an RNA virus that mutates quickly. It affects about 2.7 million people in the United States (CDC). Ongoing infection with hepatitis C majorly contributes to chronic liver disease. Hepatitis C can be cured, but there's no vaccine to prevent infection. Thus, people cannot prevent ever getting the viral infection in the first place OR protect themselves from contracting the virus a second time after being cured. 

The PEI study is utilizing the highly successful new direct-acting antiviral hepatitis C drugs (90-97% cure sucess) in a correctional facility that has a 23% infection rate of hepatitis C. The study's goals are twofold; scientists plan to reduce the prevalence of hepatitis C infections in the facility as well as see how the the new medication protects patients against reinfection. The new drugs have few side effects and can be taken orally, making them much better candidates for use in correctional facitlities than previous treatments, which were "given intravenously over long periods of time, with side effects including pain, fatigue and low blood counts" (Medical Xpress). 
A Time Course Progression of a Chronic Hepatitis C Infection

Ongoing research focused on providing a vaccine for hepatitis C continues and was discussed in an August journal article in Current Opinion in Immunology. Since hepatitis C largely contributes to chronic liver disease, the goal of hepatitis C vaccine research is specifically preventing recurring infections, rather than to "induce sterilizing immunity" (Current Opinion in Immunology). Decreasing the overall burden of chronic liver disease is a priority.

Current potential vaccines undergoing clinical trials include:
  1. non-structural hepatitis C viral proteins that induce CD8+ T cell immunity
  2. recombinant hepatitis C viral envelope proteins that are targeted by neutralizing antibodies
Curing and then preventing future hepatitis C infections with a vaccine will be especially important for individuals in high-risk populations, like in the Canadian correctional facility. Although the role of antibodies verus T cells in providing the most protective immunity is still intensely debated, ongoing research will soon tell if developing a vaccine for hepatitis C is possible. Even more, initiatives like the PEI study could help determine whether the new direct-acting antiviral agents make T cell immunity more or less possible in preventing against hepatitis C infections. 

Check out the video below to learn more about the pathology of a hepatitis C infection. 


Source: Medical Xpress
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
PARP Inhibitors Boost Immune Efficacy
In a recent research study, precision cancer drugs called PARP inhibitors are previously known to boost the immune system were found to spark a powerful im...
NOV 13, 2019
Immunology
NOV 13, 2019
Fecal Transplant improves ASD
Our understanding of the brain-gut connection is increasing by the day. Individuals with autism spectrum disorder (ASD) also experience gastrointestinal sy...
NOV 13, 2019
Immunology
NOV 13, 2019
Making Opioids Safer
The opioid crisis results in 130 American deaths every day, and both prescribed and synthetic opioids are at the core of the epidemic.  Any other drug...
NOV 13, 2019
Cell & Molecular Biology
NOV 13, 2019
Stem Cell Derived Natural Killer T Cells as Novel and Long-term Cancer Treatment
Hematopoietic stem cells are used to create a population of Natural Killer T-cells that could sustain and renew within the immune system, and attack cancer cells....
NOV 13, 2019
Immunology
NOV 13, 2019
New Observations of a Cancer Transcriptase
New research shows a transcriptase that helps time cell death varies in expression, and is unusually localized, in cancer cells.  The transcriptase, T...
NOV 13, 2019
Immunology
NOV 13, 2019
Treating Alzheimer's? Target Microglia
The body’s own immune cells may be the common denominator in Alzheimer’s disease. In a new study of the relationship between microglia, tau pro...
Loading Comments...